3C-E Stats & Data

3C‑E is the α‑methyl homologue of escaline and sits pharmacologically between the 2C‑series and the longer‑acting DOx family; Shulgin explicitly names 3C‑E as the amphetamine analogue of escaline. Verify identity: ‘3C’ compounds are rare; use multiple reagents and, where possible, a drug checking lab; single‑reagent outcomes can be misleading and some related phenethylamines show weak or absent Marquis reactions. Oral dosing tends to be smoother; insufflation commonly increases stimulation and lingering wakefulness. Community bioassays describe a bimodal profile: mescaline‑like color/visual warmth with noticeable peripheral stimulation (jaw tension, sweating, mild hypertension). Body‑load is dose‑dependent; higher oral doses (≥50 mg) and nasal use have produced nausea, tremor, and vascular tightness in reports—start low, dose once, and allocate ≥12 h without responsibilities. Plan cooling, hydration, and breaks from exertion; avoid hot environments and vigorous exercise during peak. Avoid combining with other stimulants; combinations (even small boosters) can markedly raise heart rate and prolong stimulation. Lithium has a unique, well‑documented risk of seizures when mixed with serotonergic psychedelics; do not combine. Tramadol and bupropion lower seizure threshold; avoid or exercise strict caution. Allow at least 2–3 weeks between sessions to reduce tolerance and after‑effects (insomnia, headache). No formal human PK data exist; anecdotal back‑calculation suggests an elimination half‑life on the order of several hours, with active O‑desethyl metabolites possible. Perform an allergy test (1–2 mg) with any new batch and use a milligram scale or volumetric dosing—eyeballing is unsafe.